Figure 4
Figure 4. In vitro T-cell expansion. Two batches of PBMCs from each donor were peptide-stimulated (10 µmol/L) over a course of 9 days. The first batch was analyzed on day 16 without further restimulation. The second batch was restimulated with CD3/CD28-coated beads on day 14 and analyzed on day 21. Cells were analyzed using dextramer staining on day 0 (ex vivo), day 16 (first batch), and day 21 (second batch). After gating cells with the forward and side light scatter properties of lymphocytes, dextramer-positive cells were measured as percentage of CD3/CD8-positive cells. Empty dextramer was used as negative control; CMV-pp65 was used as positive control. (A) Fluorescence-activated cell sorter (FACS) dot plots of representative female subject UPN T6. (B) FACS dot plots of representative male subject UPN T14.

In vitro T-cell expansion. Two batches of PBMCs from each donor were peptide-stimulated (10 µmol/L) over a course of 9 days. The first batch was analyzed on day 16 without further restimulation. The second batch was restimulated with CD3/CD28-coated beads on day 14 and analyzed on day 21. Cells were analyzed using dextramer staining on day 0 (ex vivo), day 16 (first batch), and day 21 (second batch). After gating cells with the forward and side light scatter properties of lymphocytes, dextramer-positive cells were measured as percentage of CD3/CD8-positive cells. Empty dextramer was used as negative control; CMV-pp65 was used as positive control. (A) Fluorescence-activated cell sorter (FACS) dot plots of representative female subject UPN T6. (B) FACS dot plots of representative male subject UPN T14.

Close Modal

or Create an Account

Close Modal
Close Modal